AMRX three-lens brief
Evidence-based stock research on AMRX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved -2.20% yesterday. · Trading >3% below the 50-day MA — short-term weakness.
- Moved -2.20% yesterday.
- Trading >3% below the 50-day MA — short-term weakness.
- Underperforming SPY by 15.6pp over 30 days.
- Analyst mean target $21.33 — 26% above current (6 analysts).
- Negative free cash flow last quarterly (-$115.33M).
AMRX closed at $16.87 (-2.20%) as of 2026-09-11. Market cap: $5.88B. P/E (trailing) 35.9. Price is below the 50-day MA and above the 200-day MA. Positives: analyst mean target $21.33 — 26% above current (6 analysts).. Concerns: moved -2.20% yesterday.; trading >3% below the 50-day MA — short-term weakness.. Last quarter: Revenue $796.20M, net income $57.66M, free cash flow -$115.33M.
Why three lenses on AMRX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AMRXacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AMRX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AMRX brief"></iframe>